CD34 and myocardial infarction: Liu et al. [125] designed a bispecific antibody (PT-BsAb) that targeted both hematopoietic stem cells (HSCs) via CD34 and platelets via CD42b to redirect lung-resident HSCs to the injured heart after acute myocardial infarction.